An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Summary

This is a Phase 1 open-label, dose escalation trial designed to identify the recommended phase 2 dose of STI-6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with relapsed or refractory systemic AL Amyloidosis

Timeline

Start

2023-09

Primary completion

2024-09

Completion

2024-11

Outcome

Outcome not reported

Stopped: “Sorrento Therapeutics filed for chapter 11 bankruptcy.”

Drugs

Indications